JDRF (The Juvenile Diabetes Research Foundation) logo

JDRF (The Juvenile Diabetes Research Foundation)

North America, New York, United States, New York

Description

JDRF is a global organization dedicated to funding type 1 diabetes (T1D) research.

Investor Profile

JDRF (The Juvenile Diabetes Research Foundation) has made 9 investments, with 0 in the past 12 months and 44% as lead.

Stage Focus

  • Grant (78%)
  • Series A (11%)
  • Series Unknown (11%)

Country Focus

  • United States (67%)
  • Canada (22%)
  • Sweden (11%)

Industry Focus

  • Biotechnology
  • Health Care
  • Diabetes
  • Medical
  • Pharmaceutical
  • Gamification
  • Gaming
  • Online Games
  • Genetics
  • Medical Device
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does JDRF (The Juvenile Diabetes Research Foundation) frequently co-invest with?

AM
Europe, Zug, Switzerland, Baar
Co-Investments: 1
Pfizer Venture Investments
North America, New York, United States, New York
Co-Investments: 1
The Leona M. and Harry B. Helmsley Charitable Trust
North America, South Dakota, United States, Sioux Falls
Co-Investments: 1
W.L. Gore & Associates
North America, New Jersey, United States, Newark
Co-Investments: 1
Toronto Innovation Acceleration Partners
North America, Ontario, Canada, Toronto
Co-Investments: 1
Co-Investments: 1
Orion Healthcare Equity Partners
North America, Massachusetts, United States, Boston
Co-Investments: 1
Centre for Drug Research and Development
North America, British Columbia, Canada, Vancouver
Co-Investments: 1

What are some of recent deals done by JDRF (The Juvenile Diabetes Research Foundation)?

Diatech Diabetes

Memphis, Tennessee, United States

Diatech Diabetes is a developer of monitoring systems to personalize insulin delivery for patients with diabetes.

DiabetesHealth CareMedicalMedical Device
GrantJun 22, 2023
Zucara Therapeutics

Vancouver, British Columbia, Canada

Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.

BiotechnologyDiabetesPharmaceutical
GrantJun 15, 2023
Amount Raised: $2,000,000
Diamyd Medical

Stockholm, Stockholms Lan, Sweden

Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development.

Biotechnology
GrantApr 4, 2023
Amount Raised: $5,000,000
Neurodon

Crown Point, Indiana, United States

Neurodon is a biopharmaceutical company with small molecules in IND-enabling studies for type 1 and type 2 diabetes and Alzheimer's disease.

BiotechnologyHealth CareMedicalPharmaceutical
GrantJun 3, 2022
Amount Raised: $920,000
TidePool

San Francisco, California, United States

Tidepool offers a game-based technology that enables users to decode personality traits, emotions, and short-term cognitive processes.

GamificationGamingOnline Games
GrantDec 14, 2018
Amount Raised: $6,000,000
Frequency Therapeutics

Lexington, Massachusetts, United States

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue.

BiotechnologyGeneticsHealth CareMedical
GrantFeb 22, 2018
Zucara Therapeutics

Vancouver, British Columbia, Canada

Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.

BiotechnologyDiabetesPharmaceutical
GrantFeb 8, 2018
Amount Raised: $1,000,000
ViaCyte

San Diego, California, United States

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes.

BiotechnologyDiabetesHealth CareMedicalTherapeutics
Series UnknownMay 22, 2017
Amount Raised: $10,000,000
AnTolRx

Cambridge, Massachusetts, United States

Our lead program addresses significant unmet needs in the field of Type 1 Diabetes

BiotechnologyHealth Care
Series ASep 8, 2016
Amount Raised: $4,000,000